Get the Stockscreener App
3.00
9.09%
-0.30
Genprex Inc stock is traded at $3.00, with a volume of 1.71M.
It is down -9.09% in the last 24 hours and up +23.46% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$3.30
Open:
$3.35
24h Volume:
1.71M
Relative Volume:
1.78
Market Cap:
$6.81M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.2562
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
+36.36%
1M Performance:
+23.46%
6M Performance:
-79.51%
1Y Performance:
-91.43%
1-Day Range:
$2.81
$3.3745
1-Week Range:
$2.10
$3.56
52-Week Range:
$1.71
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
3.00 | 7.49M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex, Inc. Stock (GNPX) Opinions on GPX-002 Diabetes Therapy Data - Quiver Quantitative
Aug Spikes: How does Genprex Inc score in quality rankingsFed Meeting & High Accuracy Investment Signals - baoquankhu1.vn
Take Profit: Is Genprex Inc stock a defensive play in 20252025 Sector Review & Verified Stock Trade Ideas - Bộ Nội Vụ
Genprex Regains Nasdaq Compliance but Faces Ongoing Monitoring - The Globe and Mail
MSN Money - MSN
Genprex Regains Nasdaq Compliance - TradingView — Track All Markets
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Congressman who was top 2025 stock picker buys shares of $5M company you've never heard of - MSN
Congressman Who Was Top 2025 Stock Picker Buys Shares Of $5M Company You've Never Heard Of - Benzinga
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Will Genprex Inc. stock remain a Wall Street favorite2025 Technical Patterns & Daily Oversold Stock Bounce Ideas - ulpravda.ru
Can Genprex Inc. stock beat market expectations this quarterShort Setup & Safe Entry Point Identification - ulpravda.ru
Can Genprex Inc. stock sustain market leadershipWeekly Trading Summary & AI Based Trade Execution Alerts - Улправда
PRN_FinancialWrapper | PR NewswireGenprex, Inc.Common Stock (Nasdaq:GNPX) Price Chart - FinancialContent
Why analysts upgrade Genprex Inc. stock2025 Market WrapUp & Risk Controlled Swing Alerts - ulpravda.ru
How Genprex Inc. stock reacts to inflationary pressuresJuly 2025 PreEarnings & Entry and Exit Point Strategies - Улправда
Is Genprex Inc. stock a bargain at current levelsSwing Trading Watchlist & Optimize Entry & Exit With Smart Signals - Улправда
Genprex Advances Diabetes Gene Therapy Program With Preclinical Milestones - Nasdaq
Genprex reports in vivo proof of concept for GPX-002 - BioWorld MedTech
Genprex reports positive data for diabetes gene therapy in animal studies - Investing.com Nigeria
Genprex advances GPX-002 diabetes gene therapy program - TipRanks
Genprex, Inc. Announces Updates on Diabetes Gene Therapy Program - TradingView — Track All Markets
Genprex Provides Clinical Update on Diabetes Gene Therapy Program - Barchart.com
Genprex Advances Diabetes Gene Therapy with Key Milestones Achieved in 2025 - Intellectia AI
What catalysts could drive Genprex Inc. stock higher2026 world cup usa national team semifinals young talents build up play odds analysis expert opinion - ulpravda.ru
Genprex reports positive preclinical results for GPX-002 diabetes therapy - MSN
Genprex Inc surges 9.44% amid market context - Intellectia AI
Genprex Reports Positive Preclinical Data for Diabetes Gene Therapy in Animal Studies; Shares Rise - marketscreener.com
Genprex Reports Positive Preclinical Data For Diabetes Gene Therapy Candidate GPX-002 - Nasdaq
Genprex Announces Positive Preliminary Preclinical Data from Stu - GuruFocus
Genprex reports positive data for diabetes gene therapy in animal studies By Investing.com - Investing.com South Africa
Genprex Reports Positive Preclinical Results for GPX-002 Diabetes Therapy - TipRanks
Genprex Announces Positive Preclinical Data for GPX-002 in Diabetes - TradingView — Track All Markets
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Genprex Announces Positive Preliminary Preclinical Data from Study of GPX-002 in Type 2 Diabetic Animal Studies - PR Newswire
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga Italia
Published on: 2025-12-29 06:37:03 - moha.gov.vn
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex Updates on Nasdaq Compliance Efforts - TradingView — Track All Markets
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.73%
0.92%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):